In brief
- Resilient Pharmaceuticals (formerly Lykos Therapeutics) has resubmitted its application for FDA approval of MDMA-assisted therapy for PTSD, two years after the initial rejection.
- The company did not conduct a new phase 3 trial; instead, it provided a phase 1 study with 32 healthy volunteers, an audit of the original data, and additional cardiac monitoring.
- Reviewing a resubmitted application is typically faster than a new one, though the final decision rests with the agency’s psychiatry division.
Two years after the U.S. Food and Drug Administration (FDA) stalled the first application for approval of MDMA-assisted therapy for post-traumatic stress disorder (PTSD), the company behind the treatment is trying again. Resilient Pharmaceuticals, the successor to the clinical program that was driven for decades by the nonprofit MAPS (Multidisciplinary Association for Psychedelic Studies), confirmed on August 9, 2026, the resubmission of its new drug application (NDA) to the FDA.
What the FDA requested and what has changed
In August 2024, the FDA issued a complete response letter (CRL) that did not close the door on approval but requested more evidence on three fronts: a more robust characterization of treatment safety, data on the durability of the effect over time, and measures to reduce the risk of bias stemming from the fact that participants and therapists could often guess who had received MDMA and who had received a placebo, given how difficult it is to mask the substance’s subjective effects. Instead of repeating a full phase 3 trial, Resilient has bolstered the existing dossier: a new phase 1 study with 32 healthy volunteers focused on cardiac monitoring, electrocardiograms, and QT intervals; an independent audit of the two already completed phase 3 trials; and third-party data, including records from the Department of Veterans Affairs, regarding the use of MDMA outside of the trial.
A three-decade program
The dossier is supported by research that MAPS funded from the early 1990s until 2022—two phase 3 trials and five phase 2 trials already published—with more than $150 million in donations raised since 1986. Rick Doblin, founder of MAPS, noted that “we knew the FDA wasn’t saying no, but rather not yet,” while Betty Aldworth, the organization’s executive director, emphasized that the clarity of the agency’s instructions “was earned by the researchers, therapists, and participants who believe this treatment deserves a rigorous evaluation.” In July 2026, the FDA also published final guidance on the design of clinical trials with psychedelics, a framework that now also encompasses this review.
What this implies
It is best to keep expectations tempered: there is no new phase 3 trial, and imperfect blinding—inherent to any study with a substance as recognizable as MDMA—remains a weak point that plagues much of psychedelic research. The final decision rests with the FDA’s psychiatry division, and an eventual approval could come with distribution restrictions that limit who can administer the treatment. For those closely following the use of MDMA, the episode serves as a reminder that clinical validation depends as much on efficacy as it does on methodological rigor; this is distinct from the harm reduction that any person can practice today, inside or outside of a trial.
Related previous coverage: Blinding fails in more than 85% of MDMA and placebo trials.
Source
- MAPS. MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA. Multidisciplinary Association for Psychedelic Studies, August 10, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
